CAS · 625115-55-1
Product Overview
Riociguat is a high-purity pharmaceutical-intermediates supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance: | Off-white to white solid |
|---|---|
| Assay: | 98%–102% |
| Identification: | (1) The retention time of major peak in the chromatogram of the test solution corresponds to that of the reference solution (2) 1H NMR spectrum is consistent with reference spectrum (3) X-ray powder diffraction pattern (0°–40°): diffraction peaks at 6.7°±0.2°, 9.0°±0.2°, 14.3°±0.2°, 17.7°±0.2°, 25.5°±0.2° (crystal form I) |
| Related Substances: | BA: 0.15% max RG-8: 0.15% max RG-7: 0.15% max RG-10: 0.15% max Unspecified impurity: 0.2% max Total impurities: 0.5% max |
| Residual Solvent: | Ethyl acetate: 0.5% max Methanol: 0.3% max Ethanol: 0.5% max N,N-Dimethylformamide: 0.088% max Dimethyl sulfoxide: 0.5% max |
| Water Content: | 0.5% max |
Applications
Riociguat (CAS 625115-55-1) is a pharmaceutical agent primarily used in the treatment of pulmonary hypertension, including pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It functions as a soluble guanylate cyclase (sGC) stimulator, enhancing the nitric oxide–cGMP pathway to induce vasodilation in pulmonary arteries. Riociguat is applied in oral formulations for chronic management of pulmonary hypertension, helping to improve exercise capacity, reduce pulmonary vascular resistance, and slow disease progression. It is also used in clinical research for exploring novel cardiovascular therapies targeting the sGC pathway.
Benefits
The benefits of Riociguat derive from its dual mechanism of action: direct stimulation of sGC and sensitization to endogenous nitric oxide. This results in effective vasodilation, improved pulmonary hemodynamics, and enhanced oxygen delivery to tissues. Riociguat has demonstrated clinical efficacy in increasing exercise tolerance, improving quality of life, and reducing hospitalization rates for patients with pulmonary hypertension. Additionally, its oral bioavailability and favorable pharmacokinetic profile enable convenient dosing and sustained therapeutic effects.
Conclusion
Riociguat is a targeted therapeutic agent for managing pulmonary hypertension, offering benefits through sGC stimulation and nitric oxide sensitization. Its efficacy in improving hemodynamics, exercise capacity, and patient outcomes makes it a valuable treatment in cardiovascular medicine. By addressing underlying vascular dysfunction, Riociguat remains an important compound in both clinical therapy and cardiovascular research.
Previous
5-Bromo-2-methylpyridin-3-amine丨CAS 914358-73-9
Next